Browse studies

Find your next paid study

135 recruiting studies matching your filters

Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy

This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD1…

Hematologic Malignancies

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Fred Hutchinson Cancer CenterNCT05952804

Observational

Assessing the Performance of "DCog Short", an iPad-Based Tool for Neurotoxicity Evaluation in CAR-T Cell Therapy Patients: A Pilot Study

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participant…

NeurotoxicityNeurotoxicity SyndromesHematologic Malignancy+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Beth Israel Deaconess Medical CenterNCT07403812

Bone Marrow Grafting for Leukemia and Lymphoma

The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.

LeukemiaLymphomaHematologic Diseases

Estimated

~$10 – $750

Actual pay is set by the research site.

Stanford UniversityNCT00186147

Observational

Phase I Study of Prophylactic TCRαβ+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI)…

Hematologic Malignancies

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Wisconsin, MadisonNCT07285668

Phase 1

A Phase 1, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepati…

Advanced Solid TumorsHematologic Malignancies

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Acrotech Biopharma Inc.NCT07036133

Phase 1

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-…

Hematologic MalignancyALL, ChildhoodAML, Childhood+2 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT06326463

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

Background: Gene therapy is closely followed by the U.S. Food and Drug Administration (FDA). The FDA requires researchers to conduct long-term follow-up of pe…

Cervical Intraepithelial NeoplasiaCervical NeoplasmsOropharyngeal Neoplasms+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT04266093

Phase 1

IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for…

Hematologic MalignancyLarge B-cell LymphomaAcute Lymphoblastic Leukemia+3 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Joshua Sasine, MD, PhDNCT05887167

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens Involved in Diseases and Healthy Populations)

Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations. The St…

OncologyHematologic MalignancyGastro-Intestinal Disorder+6 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Audubon BioscienceNCT05889806

Phase 2

A Phase II Randomized Trial to Optimize GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation in Older Adults With Hematological Malignancies: the PROMISE Trial

This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide…

Hematological MalignanciesGraft-versus-Host Disease (GVHD)

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of NebraskaNCT06799195

Phase 2

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)

This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan a…

Allogeneic Hematopoietic Stem Cell TransplantationAllogeneic Stem Cell TransplantationHematologic Malignancies

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of California, IrvineNCT06028828

Observational

Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions.…

Hematological MalignancyLeukemiaLymphoid Leukemia+5 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of NebraskaNCT07292272